Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

3期 已完成 NCT04577404

摘要

This is a Phase 3, international, multicenter, open-label, long-term extension study. The primary objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) for up to 96 weeks.

Number of Events of Treatment Emergency Adverse Events (TEAEs), Adverse Drug Reactions (ADRs), Severe TEAEs, TESEAs, TEAEs Leading to Discontinuation, Any TEAEs Leading to Death

up to 96 Weeks · events

Number of Subjects of Treatment Emergency Adverse Events (TEAEs), Adverse Drug Reactions (ADRs), Severe TEAEs, TESAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death

up to 96 Weeks · Participants

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of — Mapi Pharma Ltd.
• A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patient — Genzyme, a Sanofi Company
• A Study of Oxidative Pathways in MS Fatigue — University of California, San Francisco
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche
• Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Bioma — Gregory Wu
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche

全部试验